Led · Equity · Jul 2026

Calpech developed a patented technology that converts agricultural residues into carbon-encapsulated iron nanoparticles. Its nanomaterials target applications in environmental remediation, renewable energy and sustainable agriculture. The company has launched products including Ce-in Biogas, a liquid additive that can increase biogas production by up to 40%, and Ce-in Desulf, which can reduce hydrogen sulfide (H2S) presence by up to 99%. Calpech is pursuing industrialization and plans to expand production capacity supported by the current fundraising. The firm is a spin-off of the University of Alicante and is connected to the Parque Científico de Alicante. Financially, it is in an open funding round seeking €1.4 million and has just received a €400,000 tranche from BeAble Capital, bringing that investor's total commitment to €1 million.

Led · Equity · Mar 2026

Founded in 2022 as a spin-off of the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), Molecular Gate builds advanced security solutions for product labeling and packaging. Its flagship product, Polargram™, prints patented, semiconductor molecular inks into nano-structured patterns that generate unique optical effects nearly impossible to replicate with standard printing or copying techniques. Each label embeds both a visible physical security feature and a hidden digital traceability element in one scalable process, targeting industries such as food, toys, and pharmaceuticals that face high counterfeit risk. The company positions its technology as a combined physical-digital safeguard that can be integrated directly into existing packaging lines. Recent funding will be used to accelerate product development and commercial rollout in response to rising market demand for anti-fraud and supply-chain traceability solutions. Backing from specialized deep-tech investors underscores Molecular Gate’s focus on science-based IP and its ambition to become a reference provider of secure packaging technology.

Led · Equity · Dec 2025

BattBelt’s core product is a novel mechanical compression system, complemented by additional sensors, that mitigates the expansion-contraction stress experienced by lithium batteries during charge-discharge cycles. By maintaining optimal pressure, the solution prolongs battery life, increases the number of usable cycles and can boost energy density, enabling longer driving ranges or greater storage capacity per charge. The company positions its technology as a way to democratize ultra-fast charging, reduce the cost per delivered kWh, and postpone costly battery replacements, thereby fostering more sustainable energy consumption. BattBelt targets both electric mobility and stationary energy-storage markets, sectors that are expected to grow rapidly in Spain and across Europe. The startup plans to use its newly secured capital to scale industrial production of the system and pursue commercial deployments. Financially, BattBelt has just closed a €630,000 funding round; no revenue or user metrics were disclosed in the article.

Participated · Equity · Nov 2023

A4Cell has developed SPAchip®, silicon microchips designed to study live single cells in vitro without compromising cell viability. The chips can monitor multiple intracellular parameters or molecules simultaneously in real time and over extended periods. The company highlights advantages versus soluble fluorescent probes, including reduced toxicity, longer monitoring windows, and multiplexing capability. Hospitals and pharmaceutical and biotechnology companies are cited as key users of single-cell analysis for drug mechanism studies and target discovery. Management says the new funding will allow the company to intensify R&D and advance product development aimed at unlocking insights from individual living cells. CEO Elena Rivas described the investment as a crucial moment that underscores A4Cell’s commitment to expanding single-cell analysis capabilities, particularly for complex diseases like cancer.

Led · Equity · Jun 2023

ALA Diagnostics is a Spanish biotechnology company developing a blood-based in vitro diagnostic kit for early detection of multiple sclerosis. Its lead product, the ALA Diagnostics Em Kit, is based on a recombinant protein biomarker whose diagnostic activity has been validated in 598 human samples. The company plans to complete kit development, run international clinical trials, and seeks commercialization in Europe and the United States in the coming months. With the new funding it intends to open a production laboratory inside Madrid’s M-30 and build a multidisciplinary team to complete the final development stage. ALA Diagnostics was founded in 2019 and the founding team retains majority ownership; management includes CEO José Ramón Montero and neurologist Óscar Fernández. Previously the company closed an initial financing round in 2021 and earlier this year received a non-repayable grant of more than €500,000 from the European Commission to support R&D.